Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.46 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 5/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | STK17B | O94768 | 1/20 | 0.40 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12902766 | 0.87 | ATR (0.45) | ATRMAPKAPK2NAMPTMAP4K4RORC | |
| SCHEMBL2015768 | 0.85 | SYK (0.44) | ATRMAPKAPK2NAMPTMAP4K4RORC | |
| SCHEMBL14018435 | 0.85 | ATR (0.44) | ATRMAPKAPK2NAMPTMAP4K4RORC | |
| SCHEMBL29509761 | 0.85 | SYK (0.44) | ATRMAPKAPK2NAMPTMAP4K4RORC | |
| SCHEMBL19960767 | 0.84 | ATR (0.46) | ATRMAPKAPK2NAMPTMAP4K4RORC | |
| SCHEMBL18839612 | 0.84 | MAPKAPK2 (0.41) | ATRMAPKAPK2NAMPTMAP4K4RORC | |
| SCHEMBL23147986 | 0.83 | ATF1 (0.42) | ATRMAPKAPK2NAMPTMAP4K4RORC | |
| SCHEMBL29813513 | 0.83 | ATF1 (0.42) | ATRMAPKAPK2NAMPTMAP4K4RORC | |
| SCHEMBL909598 | 0.83 | AR (0.48) | ATRMAPKAPK2NAMPTRORC | |
| SCHEMBL29813512 | 0.83 | ATF1 (0.42) | ATRMAPKAPK2NAMPTMAP4K4RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197384-A1 | AZOLE COMPOUND AND ANTIFUNGAL AGENT | NIHON NOHYAKU CO., LTD. (JP) | 2025-06-19 | — | — | US | disclosed |
| EP-4495114-A1 | AZOLE COMPOUND AND ANTIFUNGAL AGENT | Nihon Nohyaku Co., Ltd. (JP) | 2025-01-22 | — | — | EP | disclosed |
| US-20240270744-A1 | NEW PYRIDO DIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | HOFFMANN-LA ROCHE INC. (US) | 2024-08-15 | — | — | US | disclosed |
| EP-4405356-A1 | PYRIDO DIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | F. Hoffmann-La Roche AG (CH) | 2024-07-31 | — | — | EP | disclosed |
| CN-117957227-A | Pyridodiazepine derivatives as GABA Aγ1 PAM | 豪夫迈·罗氏有限公司 | 2024-04-30 | — | — | CN | disclosed |
| US-20230109111-A1 | NEW PYRIDO DIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | HOFFMANN-LA ROCHE INC. (US) | 2023-04-06 | — | — | US | disclosed |
| WO-2023046877-A1 | PYRIDO DIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | F. HOFFMANN-LA ROCHE AG (CH) | 2023-03-30 | — | — | WO | disclosed |
| US-20230002372-A1 | AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) | 2023-01-05 | — | — | US | disclosed |
| US-20230002372-A1 | AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) | 2023-01-05 | — | — | US | disclosed |
| EP-4034108-A1 | AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | The Global Alliance for TB Drug Development, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| EP-2268618-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2011-01-05 | — | — | EP | disclosed |
| WO-2010144734-A1 | BENZONAPHTHYRIDINE-CONTAINING VACCINES | NOVARTIS AG (CH) | 2010-12-16 | — | — | WO | disclosed |
| WO-2009111337-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2009-09-11 | — | — | WO | disclosed |
| US-20050245503-A1 | Therapeutic heterocycles | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | disclosed |
| US-6890934-B2 | Sulfonamide compounds and uses thereof as medicines | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-10 | — | — | US | disclosed |
| EP-1458684-A2 | THERAPEUTIC HETEROCYCLES | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| US-20030171396-A1 | Sulfonamide compounds and uses thereof as medicines | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-09-11 | — | — | US | disclosed |
| WO-2003051276-A2 | THERAPEUTIC HETEROCYCLES | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | disclosed |
| US-6573274-B1 | Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-06-03 | — | — | US | disclosed |
| EP-1136492-A1 | SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230109111-A1 | NEW PYRIDO DIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | GABRA1, GABRB1, GABRA5 | ATR 2004/4885MAPKAPK2 3532/4885MAOB 481/4885 |
| US-20030171396-A1 | Sulfonamide compounds and uses thereof as medicines | PDE2A, PDE3A, PDE5A | ATR 2719/4885MAPKAPK2 1363/4885MAOB 2539/4885 |
| US-20240270744-A1 | NEW PYRIDO DIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | GABRA1, GABRB1, GABRA5 | ATR 2004/4885MAPKAPK2 3532/4885MAOB 481/4885 |
| US-20250197384-A1 | AZOLE COMPOUND AND ANTIFUNGAL AGENT | CBR3, ERG28, CBR1 | ATR 1109/4885MAPKAPK2 3462/4885MAOB 2653/4885 |
| US-20230002372-A1 | AZAINDOLE CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | AZI2, AADAC, TPMT | ATR 3134/4885MAPKAPK2 2050/4885MAOB 113/4885 |
| US-20050245503-A1 | Therapeutic heterocycles | OPRK1, RECQL, OPRM1 | ATR 3211/4885MAPKAPK2 3922/4885MAOB 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.